Drug industry analysts on Monday applauded Eli Lilly and Co.’s pending $8 billion cash deal to buy a startup that focuses on oncology, which has become a prime focus for the pharma giant in the last year.
Connecticut-based Loxo Oncology, which was founded in 2013 and went public a year later, has a cancer drug in development that recently received U.S. Food and Drug Administration "breakthrough therapy" status.
Bristol-Myers and Celgene combined will have nine products with more than $1 billion in annual sales and significant potential for growth in the core disease areas of oncology, immunology and cardiovascular disease.
State Sen. John Ruckelshaus said too many new hospitals, especially in small wealthy clusters, might be driving up the cost of health care. He said his bill was prompted by a recent effort by St. Vincent to rezone a 30-acre site in Carmel.
Hyde Park Venture Partners Principal Tim Kopp, the former CMO of ExactTarget, and David Shank, CEO of Shank Public Relations Counselors, talk about the warnings from their doctors that led them to start eating healthier and exercising.